

\*\*\*\*New release May 2010\*\*\*\*

## DiseaseINFOPACK: *Clostridium difficile* - Rest of World/Emerging markets (CAT: VADIP018)

<b>Proposal No/#PO</b>	:	<b>[Enter client specific #PO]</b>
<b>Product Name</b>	:	Comprehensive literature review/analysis of <i>Clostridium difficile</i> associated disease in "Rest of World" and emerging economies
<b>Project Initiation Date</b>	:	n/a
<b>Billable days</b>	:	n/a
<b>Initiator(s)</b>	:	[Enter client name, function and address]
<b>Therapeutic Area</b>	:	<i>Nosocomial infections</i>
<b>Product (if applicable)</b>	:	<b>CAT No: VADIP018</b> , published May 2010

## Background

*Clostridium difficile* (C.diff) infection (CDI) is an important contributor to the overall burden of hospital acquired-infections (HAIs) and is responsible for elevated morbidity and mortality in individuals > 65yrs, especially those with underlying co-morbidities. While oral vancomycin and metronidazole have been the mainstay of CDI treatment for many years, commercial manufacturers are now focusing of newer treatments including new generation antibiotics (Fidaxomicin, OPT-80) and immunological approaches e.g. passive and active vaccines.

Although information and literature pertaining to CDI is widespread in major Western markets, a lot less is known in large emerging economies and "Rest of World" markets. Obtaining such knowledge is critical to begin the formulation of a global market development strategy for newer CDI interventions.

This **DiseaseINFOPACK** is a comprehensive up-to-date review of current peer-reviewed literature in emerging economies and "Rest of World" markets extending upon previous **VacZine Analytics** analyses conducted in China and Western economies. It gives a comparative view of current C.diff epidemiology across regions and a critical appraisal of current understanding to date.

## PRODUCT CONTENTS:

Published May 2010 (CAT No: VADIP018), PAGES: ~54 MS Powerpoint slides, fully referenced/sourced. Available in .pdf form

Contents  
Authors note  
Definitions of CDI  
Report methodology  
Limitations of CDI incidence data  
Availability of CDI incidence data by region  
CDI baseline data: England  
CDI incidence: overview  
CDI incidence: outlook  
CDI incidence rates by country: cases per 10,000 patient-days  
CDI incidence rates by country: cases per 100,000 population  
CDI incidence rates by country: cases per 1,000 admissions  
Summary of CDI epidemiology studies: Rest of World/emerging  
Austria  
Belgium  
Czech Republic  
Denmark  
Finland  
Greece  
Holland  
Hungary  
Ireland  
Norway  
Poland  
Slovenia  
Sweden  
Switzerland  
Turkey  
Asia/Far East  
Middle East  
Latin America  
Bibliography  
About VacZine Analytics  
Disclaimer

## PROJECT METHODOLOGY:

**VacZine Analytics** has conducted a comprehensive secondary research to review all available information regarding *Clostridium difficile* in rest of world/emerging economies. Source materials used are English literature articles, government websites, medical bodies and associations, conference proceedings/attendance etc.

## PRODUCT PRICE:

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- USD \$4895.00/ GBP £3265.00 (Region license)\*


\*A region is North America, Europe or ROW

For orders in the UK, VAT at 17.5% will be added to final invoice total

## HOW TO ORDER:

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com)

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and the “**spiral logo**” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY:

Due to nature of this product the bibliography is proprietary to **VacZine Analytics** and available only to purchasing clients

## TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on-line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, influenza pandemic, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request or at [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

### **VacZine Analytics Of Assay Advantage Ltd**

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009



**VacZine Analytics**<sup>®</sup>  
Bringing life to vaccine strategy...

Bringing life to vaccine strategy...

[www.vacZine-analytics.com](http://www.vacZine-analytics.com)

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

